



## **Kanamycin (sulfate)**

**Catalog No: tcsc1140** 

	Available Sizes
Size: 1g	
<b>Size:</b> 59	g
	Specifications
CAS No	
25389-9	94-0
Formul	a:
C <sub>18</sub> H <sub>38</sub> I	
Pathwa	ay:
Anti-infe	
Target	
Bacteria	
Purity	/ Grade:
>98%	
Solubil	ity:
	30 mg/mL (51.50 mM)
Alterna	ntive Names:

## **Product Description**

**Observed Molecular Weight:** 

Kanamycin A monosulfate

582.58

Kanamycin (sulfate) is an aminoglycoside antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.





*In Vitro:* Kanamycin sulfate at the concentration above 0.0025% has a significant inhibition on the growth of B. bifidum and has no influence on the other four probiotics at incubation 12 h or 24 h. The optimum selective concentration of kanamycin sulfate in MRS media is 0.005% for selective enumeration of B.bifidum<sup>[3]</sup>.

In Vivo: The neurons damage of the DCN caused by kanamycin (500 mg/kg/day) is reversible and autophagy is upregulated in the neurotoxic course of kanamycin on DCN through JNK1-mediated phosphorylation of Bcl-2 pathway in rats. The serum BUN and Cr levels are both increased at the 1st day after the period of kanamycin administration. The neurons expressing LC3 are increased at 1, 7 and 14 days after kanamycin administration in comparison to the control group. Kanamycin treatment results in the increase of autophagy in a time-dependent manner<sup>[1]</sup>. Kanamycin sulfate (5 mg/kg) and sodium ampicillin (10 mg/kg) administered intramuscularly (i.m.) separately, and then together, to five pony mares, and the ampicillin concentration exceeds 5 mg/mL in inflamed synovial fluid for some 2.5 h after injection, and kanamycin sulfate concentration exceeds 2 mg/mL for 7 h in the pony<sup>[2]</sup>.

HO, 
$$H_2N$$
  $H_2N$   $H_2N$   $H_3$   $H_4$   $H_5$   $H_5$ 

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!